Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel and Carboplatin as Initial Chemotherapy for Ovarian Cancer
NCT00138242Phase 2Completed
- Sponsor
- Virginia Mason
- Start
- Dec 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Virginia Mason. Primary endpoint: Reduction rate of myelosuppression up to 24 weeks. Started Dec 2004; status: completed.
02
Drugs
docetaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00138242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138242.